

PRESS RELEASE

FOR IMMEDIATE RELEASE

July 19, 2023

FLAMMA expands its Continuous Flow capabilities in Italy

Chignolo D'Isola, Bergamo, Italy – July 19, 2023 – The Flamma Group (“Flamma”), a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry as well as a preeminent Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for the Innovator Companies, announced the expansion of its Continuous Flow capabilities with the investment of ~\$2M starting with the installation of a new suite of equipment from Microinnova, a leader in modular Continuous Flow systems.

“Flamma has been quietly growing our Continuous Flow capabilities over the past several years”, according to Massimo Verzini, Head of Global R&D at Flamma. “This new technology will provide the ability to work at a higher pressure more easily than a batch process as well as take advantage of a green process with recycling”.



The introduction of this production system equipment will be made at Flamma’s Chignolo Italian facility later this year. This was designed and built to be “partially modular” thus allowing for the exchange of reactor modules as needed. This increases the flexibility at Flamma and would allow customers to bring forth other products using different reaction requirements yet allow Flamma to produce materials using the same system in place.

Flamma previously announced in March that it was investing over \$200M over the next three years including the addition of new technologies across its sites. This is an example of Flamma’s commitment to bring value to its customers whether they are current or future customers.

Flamma has a network that consists of sites located in Europe, North America and China. They continue to develop Flamma USA in near Philadelphia to provides innovator companies the flexibility to begin early stage small molecule projects within the USA and then have the opportunity to move their project to other parts of the Flamma Group as the project grows.

For further information, please visit the Flamma website at <http://www.flammagroup.com>

Flamma contact: Kenneth Drew, Ph.D., VP Flamma USA
ph. 1-617-515-0975 or email: ken.drew@flammagroup.com

About Flamma:

FLAMMA is a family owned & run, fully integrated CMO based in Bergamo (near Milan in Northern Italy) established in 1950.

FLAMMA is a company specialized in the cGMP manufacture of APIs, NCEs, RSMs, and advanced intermediates for the pharmaceutical industry. Flamma has particular expertise in high value chiral materials specifically amino acid related materials. Flamma also manufactures specialty compounds and advanced intermediates for the nutraceutical and cosmetic industries and has several generic products.

FLAMMA has five manufacturing facilities- Italy (3), China, and the USA. The cGMP Italian locations (Chignolo, Isso and Bulciago) are regularly inspected by the FDA and AIFA. Flamma Honkai, located in Dalian, China, is a cGMP manufacturing facility that has been inspected by Chinese National Medical Products Administration (NMPA) formally known as the Chinese FDA. Flamma provides security when working in China with our 100% owned, self-managed facilities that deliver results without worry. Flamma reliably supplies materials directly to customers and/or delivers materials to its cGMP facilities in Italy in order to deliver the customer's compound on-time and with the desired specifications. Flamma offers cost-effective services to customers looking for a trusted partner within China.

Flamma USA is located in Malvern, PA outside of Philadelphia. This site provides Flamma with the ability to service customers looking to keep materials in the USA for pre-clinical/early stage clinical development including HPAPIs as well as low volume commercial materials.

Being a fully integrated company allows Flamma to move customer compounds quickly along their journey by taking into consideration all aspects necessary for the success of customer's projects.

Flamma can be of assistance for early stage pre-clinical development of small molecules as well as for large-scale commercial manufacturing. With a total reactor capacity of 1,100 m³ and over 800 employees, see why Flamma should be your next contract manufacturer.

FLAMMA - THE THINKING CDMO

For more information, please visit:

<https://www.flammagroup.com>

<https://www.linkedin.com/company/flamma-spa>

<https://twitter.com/flammagroup>

<https://www.facebook.com/TheFlammaGroup>